The Author Replies  by Haas, Martin H.
Coronary artery calcification and
cardiovascular mortality in
predialysis patients
To the Editor: In a recent commentary1 on Dr Chiu’s study,2
Dr Haas underlines that for the ﬁrst time an association
between all-cause mortality and coronary artery calciﬁcation
(CAC) score has been ascertained in chronic kidney disease
(CKD) patients. We recognize the clinical relevance of the
referred study.2 However, mortality rate has been previously
evaluated in a cohort of 388 CKD patients (stages: 2–5; 16%
diabetics).3 We agree with Dr Haas that all-cause mortality
might have hidden the cases due to cardiovascular events in
Dr Chiu’s study. Nevertheless, it has been observed that
‘calciﬁed’ CKD patients presented higher cardiovascular
mortality compared with noncalciﬁed controls.3 In addition,
cardiovascular mortality rate was similar, both in patients
with CAC score 4100 and 4400 (Agatston Unit),3 under-
lining the fact that CKD patient is more vulnerable, likely
having a lower threshold for cardiovascular risk.
Dr Haas addresses very interesting questions on potential
ways of inﬂuencing and/or reversing progression of CAC
in order to improve survival. Despite some limitations,
two studies may shed light on this challenging matter. In
CKD patients not yet on dialysis, Sevelamer signiﬁcantly
reduced CAC progression after a mean observation period
of 24 months.4 Faster CAC progression was independently
associated to higher cardiovascular mortality.5 Whether inter-
ventions able to reduce or reverse CAC progression may
improve survival remains to be an unanswered question so
far. Large interventional studies are needed on this critical
issue in CKD patients not yet on dialysis.
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The Author Replies: I thank Russo et al.1 for pointing to
their previous report on the association between coronary
calciﬁcation and mortality in stage 2–5 chronic kidney disease
patients in their letter to the editor.2 The study was originally
designed to describe the association between pulse pressure
and CAC, but in patients with higher CAC an increased
mortality was registered too. Owing to the lesser amount of
diabetics and a shorter follow-up the mortality rate was about
40% lower than in the study of Chiu et al.3 The study was
therefore probably underpowered for ﬁnding signiﬁcant
differences in mortality between CAC groups. It nevertheless
supports the results of Chiu et al. and further strengthens the
importance of interventional studies in these patients.
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Recurrent tartaric acid acidosis?
To the Editor: The case report ‘Recurrent metabolic acidosis
in a dialysis patient’1 attributes anion gap metabolic acidosis
to the ingestion of ‘Ahoj Brause’ (a powder that ‘ﬁzzes’ when
added to water). It contains tartaric acid, NaHCO3, and
carbohydrate. ‘Fizzing’ results from NaHCO3 reacting with
protons released from tartaric acid.
Dissolved tartaric acid releases two protons; they react with
NaHCO3 to form Na2 tartrate, CO2, and H2O. Although
ingestion of tartaric acid could generate anion gap acidosis (if
not metabolized nor excreted), the ingestion of Na tartrate
will not cause acidosis (and if metabolized, would generate
NaHCO3).
Each packet of Ahoj Brause contains 1044mg tartaric acid
(MW 150.1mg/mmol) or 7mmol¼ 14mEq and 696mg
NaHCO3 (or 8.3mEq). After reacting, the solution will contain
5.7mEq tartaric acid and 8.3mEq Na tartrate. Therefore, 10
packs per day of Ahoj Brause provide 57mEq/day tartaric acid.
If absorbed, and not metabolized, this could generate an anion
gap acidosis. The patient was treated with 100mEq/day of
NaHCO3. This should have more than offset the tartaric acid
load but ‘did not improve the acidosis’.
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